SUVRETTA CAPITAL MANAGEMENT, LLC 13D and 13G filings for Marinus Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-02-11 8:45 pm Purchase |
2025-02-07 | 13G | Marinus Pharmaceuticals, Inc. MRNS |
SUVRETTA CAPITAL MANAGEMENT, LLC | 3,022,612 5.500% |
917,348 (+43.57%) |
Filing |
| 2025-02-11 8:20 pm Sale |
2024-12-31 | 13G | Marinus Pharmaceuticals, Inc. MRNS |
SUVRETTA CAPITAL MANAGEMENT, LLC | 2,105,264 3.800% |
-3,358,377 (-61.47%) |
Filing |
| 2024-02-13 12:13 pm Purchase |
2023-12-31 | 13G | Marinus Pharmaceuticals, Inc. MRNS |
SUVRETTA CAPITAL MANAGEMENT, LLC | 5,463,641 9.990% |
491,981 (+9.90%) |
Filing |
| 2023-02-13 10:11 am Purchase |
2022-12-31 | 13G | Marinus Pharmaceuticals, Inc. MRNS |
SUVRETTA CAPITAL MANAGEMENT, LLC | 4,971,660 9.990% |
2,332,885 (+88.41%) |
Filing |
| 2022-02-11 5:25 pm Purchase |
2021-12-31 | 13G | Marinus Pharmaceuticals, Inc. MRNS |
SUVRETTA CAPITAL MANAGEMENT, LLC | 2,638,775 7.200% |
586,417 (+28.57%) |
Filing |
| 2021-08-20 4:36 pm Purchase |
2021-08-10 | 13G | Marinus Pharmaceuticals, Inc. MRNS |
SUVRETTA CAPITAL MANAGEMENT, LLC | 2,052,358 5.600% |
2,052,358 (New Position) |
Filing |